Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review

• Published in: Rheumatology (Oxford, England) Vol. 63; no. 2; pp. 285 - 297
• Main Authors: Hysa, Elvis, Bond, Milena, Ehlers, Lisa, Camellino, Dario, Falzon, Louise, Dejaco, Christian, Buttgereit, Frank, Aletaha, Daniel, Kerschbaumer, Andreas
• Format: Journal Article
• Language: English
• Published: England 01.02.2024
• Subjects: treat to target; GCA; PMR; T2T
• ISSN: 1462-0324; 1462-0332
• DOI: 10.1093/rheumatology/kead471

To inform an international task force about current evidence on Treat to Target (T2T) strategies in PMR and GCA. A systematic literature research (SLR) was conducted in Medline, EMBASE, Cochrane Library, clinicaltrials.gov from their inception date to May 2022, and in the EULAR/ACR abstract database (2019-2021). Randomised clinical trials (RCTs) and non-randomised interventional studies published in English and answering at least one of the eleven PICO questions on T2T strategies, treatment targets and outcomes, framed by the taskforce, were identified. Study selection process, data extraction and risk of bias assessment were conducted independently by two investigators. Of 7809 screened abstracts, 397 were selected for detailed review and 76 manuscripts were finally included (31 RCTs, eight subgroup/exploratory analyses of RCTs and 37 non-randomised interventional studies). No study comparing a T2T strategy against standard of care was identified. In PMR RCTs, the most frequently applied outcomes concerned treatment (90.9% of RCTs), particularly the cumulative glucocorticoids (GC) dose and GC tapering, followed by clinical, laboratory and safety outcomes (63.3% each). Conversely, the most commonly reported outcomes in RCTs in GCA were prevention of relapses (72.2%), remission as well as treatment-related and safety outcomes (67.0% each). This SLR provides evidence and highlights the knowledge gaps on T2T strategies in PMR and GCA, informing the task force developing T2T recommendations for these diseases.